Pfizer Raises EPS Guidance and Expands Cost-Cutting Plan While Boosting Dividend Appeal

Pfizer Inc. (NYSE:PFE) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In.

The company raises its Adjusted Diluted EPS guidance and raises its total savings goal amid a revenue increase in Q2 2025.

Pfizer Inc. (NYSE:PFE)’s second-quarter results were reported on August 5, 2025, where it highlighted a year-over-year increase in revenue of 10%, reaching $14.7 billion. The revenue growth was partly contributed to by continued strong demand and growth for the Vyndaqel family of drugs due to increased diagnosis and treatment rates.

Following the strong quarter, the company announced raising its full-year 2025 adjusted diluted EPS guidance by $0.10 to a range of $2.90 to $3.10. Furthermore, the company raised its cost-cutting target with an additional $1.7 billion in savings through 2027. This increase raised the total savings goal to $7.7 billion. The company anticipates realizing approximately $4.5 billion of these savings by the end of 2025.

Pfizer Inc. (NYSE:PFE) tops our list of 13 best Fortune 500 dividend stocks to invest in, by offering an attractive dividend yield of 7.20%.

Pfizer Inc. (NYSE:PFE) is a global pharmaceutical and biotechnology corporation, headquartered in New York. The company was formed in 1849 and focuses on developing and manufacturing a wide range of medicines and vaccines for various therapeutic areas, including oncology, cardiology, and immunology.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Performing IPOs in the Last 2 Years and 12 Jim Cramer Stock Picks this Week

Disclosure. None.